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Publications No. ____________ 
 
Laura Godfrey Hendon, MA 
 
Supervisory Professor:  Kate Wilson, MS, CGC 
 
 Mood disorders are the most common form of mental illness and one of the leading 
causes of morbidity worldwide.  Major depressive disorder and bipolar disorder have a 
lifetime prevalence of 16.2% and 4.4%, respectively.  Women comprise a substantial 
proportion of this population, and an estimated 500,000 pregnancies each year involve 
women with a psychiatric condition.  Management with psychotropic medications is 
considered standard of care for most patients with mood disorders.  However, many of these 
medications are known human teratogens.  Because pregnant women with mood disorders 
face a high risk of relapse if unmanaged, the obstetrician faces a unique challenge in 
providing the best care to both mother and baby. 
 It has been suggested that many obstetricians overestimate the teratogenic risks 
associated with psychotropic medications, while concurrently underestimating the risks 
associated with unmanaged mood disorders.  This may be due a knowledge gap regarding 
the most current teratogen information, and lack of official management guidelines.  
Therefore, the purpose of this study is to determine the current knowledge base of 
obstetricians regarding the teratogenic effects of common psychotropic medications, as 
wells as to capture current management practices for pregnant women with mood disorders. 
 A total of 117 Texas obstetricians responded to a survey regarding teratogen 
knowledge and management practice.  It was common for respondents to encounter women 
who disclose both having a mood disorder and taking a psychotropic medication during 
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pregnancy.  Many respondents did not utilize up-to-date drug counseling resources, and 
were unaware of or over-estimated the teratogenic risks of common medications used to 
treat mood disorders.  Finally, many respondents reported wanting to refer pregnant patients 
with mood disorders to psychiatrists for co-management, but are reportedly restricted in 
doing so due to accessibility or insurance issues.   
 This study demonstrates that there is a knowledge gap among obstetricians regarding 
the teratogenicity of common psychotropic medications utilized to manage a patient 
population they frequently encounter.  Further, obstetricians have vastly different risk 
perceptions of these medications, resulting in various management approaches and 
recommendations.  Future research should focus on establishing standard practice 
guidelines, as well as better accessibility to psychiatric services for pregnant women. 
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BACKGROUND 
 
 Psychiatric disorders are one of the leading causes of morbidity in the world.  Mood 
disorders or affective disorders are the most common form of mental illness and include 
major depressive disorder and bipolar disorder or manic-depressive illness, (Craddock & 
Forty, 2006).  Major depressive disorder (MDD) is defined as one or more incidences of 
persistent depression accompanied by symptoms such as insomnia, fatigue, and suicidal 
ideation that last more than two weeks (Marchesi, Bertoni, & Maggini, 2009).  Bipolar 
disorder (BPD) is characterized by alternating episodes of major depression and either 
mania (bipolar I disorder) or hypomania (bipolar II disorder).  Mania is an elevated mood 
state characterized by irritability, feelings of grandeur, and an increase in goal-directed 
behavior (Benazzi, 2007).   
Individuals with mood disorders have high incidences of comorbid mental conditions 
such as anxiety disorder and obsessive-compulsive disorder (Kessler, Merikangas, & Wang, 
2007).  Further, it is widely recognized that among all types of mental illness, the highest 
incidences of comorbid substance abuse and suicide are found in mood disorders (Bertolote, 
Fleischmann, De Leo, & Wasserman, 2004; Tohen, Greenfield, Weiss, Zarate, & Vagge, 
1998).  The 2004 National Comorbidity Survey Replication estimates a lifetime prevalence 
of 16.2% for MDD and 4.4% for BPD (Kessler, et al., 2007).  Women comprise a 
substantial proportion of this population.  While BPD has an equal prevalence between 
genders (Burt & Rasgon, 2004), MDD is twice as common in women (Kessler, 2003) and is 
the leading cause of female disease-related disability worldwide (Lopez & Mathers, 2006).   
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Mood disorders and pregnancy  
The management of women with mood disorders presents unique challenges to the 
health care provider, especially the obstetrician (Burt & Rasgon, 2004).  Most individuals 
with MDD and BPD are diagnosed during their reproductive years.  The average age of 
onset is 32 years old for MDD and 18 and 20 years old for type I and type II BPD, 
respectively (Kessler, et al., 2007).  The American College of Obstetricians and 
Gynecologists (ACOG) estimates that more than 500,000 pregnancies each year involve 
women with psychiatric conditions (ACOG, 2008).    Between 14 and 23% of pregnant 
women are affected by a depressive disorder during pregnancy (Yonkers et al., 2009).  In 
addition, as much as 20% of the pregnant population will experience either the relapse of a 
previous psychiatric condition or the onset of new symptoms during pregnancy (Frieder, 
Dunlop, Culpepper, & Bernstein, 2008).  A 2002 survey of 14,549 pregnant woman in the 
United States found an 8.4% and 2.8% incidence of MDD and BPD, respectively, during 
pregnancy and postpartum (Vesga-Lopez et al., 2008).  It is possible that our current 
approximation of the incidence of MDD during pregnancy is an underestimate, as women 
with MDD are less likely to present for prenatal care (Bennett, Einarson, Taddio, Koren, & 
Einarson, 2004) or may lack an official diagnosis at presentation.  Indeed, as many as 70% 
of women report depressive symptoms during pregnancy (ACOG, 2008).  
While post-partum depression is now widely recognized and treated, the incidence 
and impact of mood disorders during pregnancy is just beginning to be evaluated (Yonkers, 
et al., 2009; Yonkers et al., 2004).  A 2004 meta-analysis of 19,284 pregnant patients found 
that the rate of MDD in the second and third trimesters of pregnancy is nearly double that of 
the normal female population (Bennett, et al., 2004).  Bennett and colleagues recognize that 
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typical symptoms of pregnancy can be difficult to separate from those of MDD, however, 
they report success using validated questionnaires such as the Beck Depression Inventory.  
Mood disorders have serious clinical effects on pregnancy.  Depressive episodes during 
gestation are associated with an increased risk for pre-eclampsia, pre-term birth, and low 
birth weight infants (Wisner, 2010)  Overall, affected women have poorer pregnancy 
outcomes, higher rates of post-partum mental illness, and an increased risk for substance 
abuse and lack of prenatal care (Frieder, et al., 2008; Wisner, 2010). 
 
Accessibility and utilization of mental health resources 
 It is estimated that up to 40% of individuals with mental health problems initially 
present for care to their primary care physician (Smalley et al., 2010).  Coupled with the 
average age of onset for mood disorders, it is therefore likely that many women present 
symptoms for the first time to their obstetrician/gynecologist.  Perhaps even more common 
is the pregnant woman taking a psychotrophic medication originally prescribed by a primary 
care physician, but not receiving any long-term professional management or surveillance by 
a psychologist or psychiatrist.  Obstetricians may play an important role in identifying 
pregnant women with mood disorders and referring them to psychiatric care for symptom 
management, cognitive behavioral therapy, and recommendations on drug therapy during 
pregnancy. 
 However, it is estimated that only 25-35% of pregnant women with a mood or 
anxiety disorder receive mental health treatment (M. V. Smith et al., 2009).  In fact, 
pregnant women are less likely than non-pregnant women to receive psychiatric care 
(Vesga-Lopez, et al., 2008).  The management of women with mood disorders may be 
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restricted by both accessibility to and utilization of mental health care resources.  A recent 
study of 315 pregnant women referred for mental health services found that only 35.6% 
(n=112) actually attended a mental health appointment and only 6% followed up with long-
term care (M. V. Smith, et al., 2009).  Obstetricians and physicians in certain communities 
may not even have the option to refer to a mental health care provider in the first place.  It is 
estimated that over one-half of the counties in the United States lacks a psychologist or 
psychiatrist (Smalley, et al., 2010).  Indeed, the third highest overall area and number one 
specialty area of healthcare service shortage in rural America is psychiatry (MacDowell, 
Glasser, Fitts, Nielsen, & Hunsaker, 2010).  In addition to accessibility, individuals with 
mood disorders face additional challenges in obtaining proper care, including inadequate 
insurance coverage, high cost of treatment, unavailability of generic drugs for many 
commonly prescribed psychotrophics, under-recognition or misdiagnosis of symptoms, and 
fear of cultural or societal stigmatization (Bhugra & Flick, 2005).  
 A recent case study of a young woman with type I bipolar disorder who successfully 
managed her illness through two pregnancies suggests the “key treatment components” for 
mood disorder management during pregnancy include an intimate and long-term 
relationship with a psychiatrist, access to excellent perinatal care and monitoring, and 
familial and financial support (Burt, Bernstein, Rosenstein, & Altshuler, 2010).  This array 
of resources is not available to many patients.    
 Further studies are needed on the availability and utilization of mental health care 
resources by pregnant women, as well as an evaluation of the referral patterns of 
obstetricians who treat women with mood disorders. 
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Pharmacological treatment of mood disorders and pregnancy risks 
 In addition to cognitive behavioral therapy, pharmacological therapy is also 
considered standard of care in the treatment of moderate to severe mood disorders.  
Common medications for the management of MDD and BPD include selective serotonin 
reuptake inhibitors (SSRIs), anti-epileptic drugs (AEDs) that act as mood stabilizers, and 
atypical antipsychotics (ACOG, 2008).  While effective, many of the drugs in these classes 
are known human teratogens or associated with adverse neurobehavioral outcomes in the 
fetus (Frieder, et al., 2008).  Obstetrician knowledge of the teratogenicity of these 
medications is imperative, as ACOG estimates that one-third of all pregnancies are exposed 
at some point in gestation to a psychotropic medication (2008). 
 
Selective serotonin reuptake inhibitors (SSRIs)  
SSRIs were discovered in the 1980s, and quickly gained popularity due to their 
effectiveness in treating depression and lack of negative side effects in comparison to older 
tricyclic antidepressants (Louik, Lin, Werler, Hernandez-Diaz, & Mitchell, 2007).  SSRIs 
are now the most widely prescribed drugs in the treatment of MDD, and an estimated 13% 
of women are exposed to them during pregnancy (Yonkers, et al., 2009).  Some of the most 
common SSRIs in clinical use include citalopram (Celexa®), escitalopram (Lexapro®), 
fluoxetine (Prozac®), paroxetine (Paxil®), and sertraline (Zoloft®).  The current data 
regarding the risk for specific birth defects related to SSRI exposure is conflicting and lacks 
reproducibility (Yonkers, et al., 2009).  For example, two similar case-control studies 
published concurrently in The New England Journal of Medicine reported significantly 
discrepant results in evaluating the teratogenicity of SSRIs (Alwan, Reefhuis, Rasmussen, 
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Olney, & Friedman, 2007; Louik, et al., 2007).  Alwan and colleagues analyzed 9622 cases 
and 4092 controls from the National Birth Defects Prevention Study and found an 
association between SSRI use in pregnancy and the incidence of anencephaly, 
craniosynostosis, and omphalocele, but not congenital heart defects (2007).  In contrast, 
Louik and colleagues’ evaluation of data from the Slone Epidemiology Center Birth Defects 
Study (9849 cases and 5860 controls), found no association between maternal SSRI use and 
anencephaly, craniosynostosis, ompahlocele, or congenital heart defects overall, but a 
significant association with the use of paroxetine and right ventricular outflow tract 
obstruction defects (Louik, et al., 2007).   
 The association between prenatal exposure to paroxetine and heart defects was first 
widely reported in a 2007 study of the Swedish Medical Birth Register (B. A. Kallen & 
Otterblad Olausson, 2007).  This study reported a 1.5 to 2-fold increased risk for cardiac 
malformations in infants exposed to paroxetine and thus raised concern about the safety of 
SSRIs during pregnancy in general (ACOG, 2008; B. A. Kallen & Otterblad Olausson, 
2007).  However, this risk was calculated from retrospective analyses of birth and insurance 
registries and attempts to replicate this finding in large cohort studies have been 
unsuccessful (Yonkers, et al., 2009).  The overall risk for structural abnormalities due to 
SSRIs is still considered low at 2 per 1,000 births (ACOG, 2008).  
Transient neonatal “withdrawal” symptoms consisting of irritability, tachypnea, 
hypoglycemia, temperature instability, and seizures have been described in newborns 
exposed to SSRIs (Chambers, Johnson, Dick, Felix, & Jones, 1996; Costei, Kozer, Ho, Ito, 
& Koren, 2002; Oberlander, Warburton, Misri, Aghajanian, & Hertzman, 2008).  However, 
these symptoms typically resolve within two weeks and no long-term neurobehavioral 
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outcomes have been observed in children or adults that were exposed in utero (Gentile & 
Galbally, 2010).  The use of SSRIs has also been associated with low birth weight and 
preterm babies, but these outcomes are also seen in offspring of women with MDD not 
exposed to medication (ACOG, 2008; Yonkers, et al., 2009). 
 Currently, ACOG recommends that women avoid taking paroxetine during 
pregnancy, and physicians should consider monitoring those pregnancies exposed in the first 
trimester to the drug with fetal echocardiography (2008).  There are no established 
guidelines for the use of other SSRIs during pregnancy.  ACOG suggests physicians take an 
“individualized” approach to outlining treatment plans, and consider both the potential risks 
of the medication and the severity of maternal illness when managing women with MDD 
(2008). 
  
Anti-epileptics (AEDs)  
In contrast to SSRIs, the teratogenicity of several AEDs is firmly established from 
studies in the epileptic population.  It is estimated that 45,000 children have been exposed to 
AEDs in the United States alone (Kluger & Meador, 2008).  Valproic acid (Depakote®) is 
one of the oldest and most effective AEDs used as a mood stabilizer in BPD.  However, 
VPA is considered the most teratogenic anti-convulsant on the market (Ornoy, 2006).  An 
increased incidence of spina bifida in infants exposed to VPA in utero was first observed in 
the early 1980s (Bjerkedal et al., 1982; Dalens, Raynaud, & Gaulme, 1980; Gomez, 1981).  
Since then, numerous studies have reported an association between VPA exposure and 
multiple major anomalies including cardiac, skeletal, craniofacial, and limb defects (Kluger 
& Meador, 2008).   
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 A 1992 prospective cohort study of 300 women found that 9.4% of pregnancies 
exposed to VPA had a major malformation, including six cases of spina bifida (6.3%) 
(Omtzigt et al., 1992).  Similarly, an evaluation of the 3,441 women in the North American 
Antiepileptic Drug Pregnancy Registry found that those exposed to VPA during pregnancy 
had a 7.3 relative risk to have a baby with a major congenital malformation in comparison to 
women taking other AEDs during pregnancy (Wyszynski et al., 2005).  Further, birth 
registries in Finland and the United Kingdom (UK) found a 4.6% and 6.2% incidence of 
major malformations, respectively, in those pregnancies exposed to VPA (Artama, Auvinen, 
Raudaskoski, Isojarvi, & Isojarvi, 2005; Morrow et al., 2006).  Six children exposed to VPA 
in the Finland study (7%) and seven in the UK study (1%) had spina bifida (Artama, et al., 
2005; Morrow, et al., 2006).  Overall, a 1-2% risk for neural tube defects and up to a 10% 
risk for any major congenital malformation is typically quoted to patients receiving 
counseling for pregnancies exposed to VPA (Kluger & Meador, 2008; Ornoy, 2009).   
There is a known dose-dependent relationship between VPA and an increased 
incidence of birth defects.  Adverse pregnancy outcomes are unlikely to occur in women 
receiving less than 1,000 mg a day (J. Smith & Whitehall, 2009).  The incidence of birth 
defects, including NTDs, is considered increased above the background when daily doses 
reach 1,400 mg or higher (Ornoy, 2009; J. Smith & Whitehall, 2009).  While VPA is a 
known folic acid antagonist, no studies of VPA have demonstrated a decrease in the rate of 
neural tube defects after supplementing with 4-5 mg/day of folic acid (Ornoy, 2009). 
 In addition to congenital anomalies, VPA exposure is associated with other risks. 
DiLiberti and colleagues first described a unique pattern of dysmorphic facial features and 
mental impairments in a group of seven children exposed to VPA in utero (1984).  Features 
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of what is now termed “fetal anticonvulsant syndrome” or “anti-epileptic drug (AED) 
syndrome” are often seen in children exposed to AEDs in utero (Ornoy, 2009).  Facial 
findings include a smooth, long philtrum with thin upper lip, midface hypoplasia, flat nasal 
bridge, small anteverted nose, down-turned angles of the mouth, and thin arched eyebrows 
(DiLiberti, et al., 1984; J. Smith & Whitehall, 2009).  Children with features of AED 
syndrome often have other congenital anomalies and cognitive delays.  It is unknown the 
exact percentage of children exposed to VPA in utero that develop AED syndrome.  A study 
by Kini and colleagues found that of 274 children exposed to AEDs, 47% were correctly 
identified by dysmorphologists as being exposed based on their unique facial features (Kini, 
Adab, Vinten, Fryer, & Clayton-Smith, 2006). 
Many children exposed to VPA will also have developmental delays and learning 
problems.  Some studies have reported lower verbal intelligence quotient scores (J. Smith & 
Whitehall, 2009).  An association between VPA exposure and the development of autistic 
spectrum disorder (ASD) has been frequently reported (Ornoy, 2006).  A 2005 study found 
that the incidence of ASD, including pervasive developmental disorder and Asperger 
syndrome, is about 20 times higher in those exposed to VPA than in the general population.  
Of 56 children exposed to VPA in utero, 8.9% met a DSM-IV diagnosis of ASD (Rasalam et 
al., 2005).  Finally, about 20% of infants exposed to VPA in utero will experience 
withdrawal symptoms after birth, similar to the transient neonatal withdrawal response seen 
with SSRI exposure (J. Smith & Whitehall, 2009).  When VPA use during pregnancy cannot 
be avoided, the lowest effective dose possible prescribed in 2-3 divided doses is considered 
the best course of treatment (Ornoy, 2009). 
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 In addition to VPA, the AED carbamazepine (Tegretol®) is also considered 
teratogenic due to an association with neural tube defects and syndromic facial features 
(Dodd & Berk, 2006).  A 1991 meta-analysis of 984 pregnancies exposed to carbamazepine 
found 9 cases of spina bifida, suggesting an approximately 1% risk for neural tube defects 
(Rosa, 1991).  More recently, the United Kingdom Pregnancy Registry reported an overall 
2.3% malformation rate for pregnancies exposed to carbamazepine (n=700) (Kaplan, 2004).  
Multiple congenital anomalies including cardiac defects, skeletal malformations, cleft lip 
and palate, and brain anomalies have also been reported in exposed infants (Ornoy, 2006). 
Based on current knowledge of VPA and carbamazepine in the epileptic population, 
these medications are not recommended as first-line therapy in the treatment of BPD in 
women of reproductive age.  Lamotrigine (Lamictal®), introduced in the late 1990s, is not 
believed to be associated with an increased risk for birth defects (Cunnington, Ferber, & 
Quartey, 2007)  and is currently considered the safest BPD treatment option during 
pregnancy (ACOG, 2008).  Pooled data from studies performed from 2003 to 2007 suggests 
a 2.6% incidence of major malformations following first-trimester exposure to lamotrigine, 
which is below the universal 3-5% background risk for birth defects in any pregnancy 
(Newport et al., 2008).  Among these studies, the pooled risk for orofacial clefts was 0.34% 
(Newport, et al., 2008).  A recent study of the Australian Register of Antiepileptic Drugs in 
Pregnancy found the incidence of birth defects in pregnant women who took lamotrigine 
(n=243), carbamazamine (n=302), and valproic acid (n=224) to be 4.9%, 5.3%, and 15.2%, 
respectively (Vajda et al., 2010).  The incidence of birth defects related to lamotrigine was 
similar to that of women who did not take an AED during pregnancy (Vajda, et al., 2010).  
While further studies are needed, Newport and colleagues felt that lamotrigine was effective 
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in managing bipolar disorder during pregnancy.  In their study of 26 women with type II 
BPD,  the incidence of new episodes during pregnancy was only 30% in women who took 
lamotrigine compared to 100% who completely discontinued treatment during pregnancy 
(Newport, et al., 2008). 
 
Second-generation antipsychotics 
The use of second-generation (atypical) antipsychotics such as aripiprazole 
(Abilify®), clozapine (Clozaril®), and risperidone (Risperdal®)  to manage the acute manic 
episodes of bipolar disorder is becoming more common (Dodd & Berk, 2006).  Unlike the 
original (typical) antipsychotics, this group is associated with less adverse effects in the 
mother and is considered more effective in managing psychosis (Einarson & Boskovic, 
2009).  Typical antipsychotics have been in use for over 40 years (ACOG, 2008), and their 
effects on the developing fetus have been widely studied (Reis & Kallen, 2008).  In contrast, 
there is little data regarding the potential teratogenicity of atypical antipsychotics (Einarson 
& Boskovic, 2009) which were not introduced until the mid-1990s (McKenna et al., 2005) .  
One of the largest studies of exposures to antipsychotics was a 2008 analysis of the Swedish 
Birth Registry by Reis and Kallen.   This population-based study looked at 460 women who 
took typical antipsychotics and 101 women who took atypical antipsychotics during 
pregnancy for the treatment of a psychiatric disorder.  There was a slightly increased risk for 
birth defects (odds ratio of 1.5) in pregnancies exposed to typical antipsychotics, particularly 
atrial and ventral septal heart defects (Reis & Kallen, 2008).  However, there was no 
increased risk for congenital malformations in the group exposed to atypical antipsychotics, 
suggesting a lack of teratogenicity in this new class (Reis & Kallen, 2008).  In a similar 
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case-control study of 151 pregnancies exposed to atypical antipsychotics, there was no 
significant increase in birth defects in the exposed group (McKenna, et al., 2005).  However, 
there was a significant increase in the incidence of low birth weight babies in pregnancies 
exposed to antipsychotics (10%) compared to controls (2%) (McKenna, et al., 2005).  The 
rate of therapeutic abortions was also significantly higher in the exposed group (9.9%) than 
in controls (1.3%).  Of note, a significant increase in maternal weight gain has been 
observed in women exposed to atypical antipsychotics (McKenna, et al., 2005).  Indeed, 
Reis and Kallen found that women exposed to these drugs were two times more likely to 
develop gestational diabetes (2008). 
Overall, atypical antipsychotics are considered safer for pregnancy than the common 
mood stabilizers.  While further studies are needed, current data suggest they are not 
associated with an increased risk for birth defects (Dodd & Berk, 2006).  However, 
antipsychotics are rarely used as monotherapy in BPD and are often combined with another 
mood stabilizer like VPA (Dodd & Berk, 2006).  Thus, physicians must consider the 
combined teratogenicity of the two agents when assessing risk to the pregnancy.  In general, 
polytherapy is associated with poor birth outcomes (Dodd & Berk, 2006).  ACOG 
recommends the use of a single medication at a higher dose rather than multiple medications 
to manage psychiatric disease (2008).   
 
Unmanaged mood disorders and pregnancy  
Symptom recurrence 
The risks associated with pharmacological management of mood disorders during 
pregnancy must be weighed against the risks associated with discontinuing treatment.  
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Pregnancy is no longer considered to have a “protective” effect on women (Kloos, 
Kegelmeyer, Young, & Kostyk, 2010), and studies suggest it is a dangerous time for women 
with mood disorders to discontinue treatment.  Viguera and colleagues observed a 50% 
recurrence of symptoms within two weeks in women with BPD who discontinued treatment 
during pregnancy (2007).  Further, women who stopped pharmacological therapy 
experienced a new episode four times sooner than those women who maintained treatment 
(Viguera, et al., 2007).  Another study found that 68% of women who discontinued 
medication during pregnancy experienced a recurrence of MDD symptoms, compared to 
26% of patients who continued pharmacological therapy (Cohen et al., 2006).  A recent 
review article suggests women with MDD face an estimated 50-75% risk of relapse when 
discontinuing medication (Frieder, et al., 2008).   
 
Outcomes of unmanaged episodes 
Unmanaged mood disorders during pregnancy affect the fetus and the mother.  
Premature birth, low birthweight, and fetal growth restriction are associated with untreated 
depression during pregnancy (ACOG, 2008).  Mood episodes during pregnancy are also 
associated with an increased risk for substance abuse, and a higher incidence of post-partum 
psychosis, which itself is linked to higher rates of suicide and infanticide (Frieder, et al., 
2008).  Infants of mothers with unmanaged depression are more likely to present with 
increased irritability, decreased attentiveness, and increased cortisol levels compared to 
infants of non-depressed women (Yonkers, et al., 2009).  Further, offspring of women with 
untreated depression are more likely to have behavioral and emotional problems that require 
psychiatric care later in life (ACOG, 2008).  Children of women who were depressed during 
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pregnancy are more likely to have developmental delays, irrespective of whether their 
mothers experienced post-partum depression (Alwan, et al., 2007). 
 
Current management guidelines  
The treatment of pregnant women with mood disorders raises difficult questions 
about who is the primary patient in the mother-fetus pair.  Left to weigh the risks and 
benefits of pharmacological treatment during pregnancy, obstetricians often find themselves 
between a “teratologic rock and clinical hard place” (Cohen, Friedman, Jefferson, Johnson, 
& Weiner, 1994).  While no explicit guidelines exist for the management of mood disorders 
during pregnancy, recent recommendations suggest that a detailed assessment of each 
woman’s illness history, including frequency and severity of episodes, should be performed 
before decisions about maintenance therapy are made (Yonkers, et al., 2004).   
 
APA and ACOG recommendations 
The American Psychiatric Association (APA) and the American College of 
Obstetricians and Gynecologists (ACOG) recently published a report regarding the 
management of depression during pregnancy.  The report outlines the risks associated with 
both antidepressant use and unmanaged MDD during pregnancy, but does not offer explicit 
guidelines as to how these cases should be handled.  Rather, it generally states that proper 
management is dependent on case-by-case factors such as severity and duration of illness, 
and response to different forms of treatment (Yonkers, et al., 2009).  As an example of the 
report’s relative ambiguity, the authors respond to the “frequently asked question” of 
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“should women who are being treated with paroxetine prior to conception switch to an 
alternative SSRI?” with:  
the decision to continue or change medication is a collaborative one between 
the physician and the patient, and there is no universal ‘best answer’ for all 
women… the clinician should review data regarding paroxetine as outlined in 
the preceding sections, and document the discussion and the woman’s 
questions carefully in the medical record (Yonkers, et al., 2009).    
In addition to this 2009 report, ACOG also published a practice bulletin extensively 
reviewing the risks associated with the most commonly used psychiatric medications, as 
well as general clinical considerations for managing each psychiatric disease (ACOG, 2008).  
These guidelines were extensively referenced in the previous overview of commonly used 
psychotrophics. 
 
Adherence to guidelines 
While some guidelines for managing pregnant women with mood disorders currently 
exist, they are not widely followed.  It is estimated that a large proportion of women with 
mood disorders are advised by their physicians to completely stop taking medication when 
they discover they are pregnant (Einarson & Boskovic, 2009; Viguera, et al., 2007).  This 
common practice may be due to concerns of medical liability in the rare event of an adverse 
pregnancy outcome (Koren, 2001; Koren & Levichek, 2002; Webster & Freeman, 2001; 
Wisner, 2010).  In addition to physician-recommended discontinuance, many pregnant 
women independently decide to stop taking prescribed medications due to fear of possible 
teratogenicity.  A study of 1793 pregnant women found that 7 out of 10 women chose not to 
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take a medication of any type during pregnancy because they felt it was unsafe (Nordeng, 
Ystrom, & Einarson, 2010).   
 
Teratology perceptions and information sources 
Fueling physician concern for adverse outcomes and the general practice of 
discontinuing medications may be misinformation about the actual teratogenic risks 
associated with the use of psychotropics during pregnancy (Koren & Levichek, 2002).  
There is a widely accepted 3-5% background risk for birth defects with any pregnancy 
(Polifka, Faustman, & Neil, 1997), and it is estimated that less than 1% of birth defects are 
due to prescription drug exposures (Webster & Freeman, 2001).   However, numerous 
studies have demonstrated that physicians and their patients often overestimate the 
teratogenicity of medications used during pregnancy (Koren & Levichek, 2002; Pole, 
Einarson, Pairaudeau, Einarson, & Koren, 2000; Webster & Freeman, 2001).   
 
Overestimation of risk 
One study found that women exposed to medications well classified as non-
teratogenic estimated their risk for birth defects to be as high as 24% (Koren, Bologa, Long, 
Feldman, & Shear, 1989).  Further, in a recent Norwegian risk perception questionnaire of 
pregnant women taking prescription drugs, 87% of women exposed to antidepressants 
during pregnancy (n=100) overestimated the teratogenicity of these medications (Nordeng, 
et al., 2010).  However, only 12% of these women overestimated their risk after receiving 
appropriate drug counseling (Nordeng, et al., 2010).  This emphasizes the need for a well-
informed health care professional to provide accurate information to anxious women who 
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may overestimate their risk prior to consultation.  Indeed, 78% of women in the Norwegian 
study acquired their drug information directly from a physician, suggesting this group is 
often the first and only educational resource for most patients (Nordeng, et al., 2010).  
However, a study of data from the Canadian teratology information Motherisk Program 
found that women referred directly from physicians did not have more accurate teratology 
risk perceptions than self-referred women (Koren & Levichek, 2002).  The authors note their 
experience with numerous cases in which physicians suggested terminations of pregnancies 
in spite of “clear information on fetal safety” (Koren & Levichek, 2002).  This suggests 
physicians themselves are misinformed or misinterpret (or both) available teratogen 
information. 
 
Outdated risk figures 
These misperceptions could be due to the pervasiveness of risk figures from the 
original studies of these medications.  For example, a 1974 study of birth defects in babies 
exposed to lithium, a mood stabilizer commonly used to manage BPD, found a 400-fold 
increase in the incidence of a rare heart defect called Ebstein’s anomaly (Cohen, et al., 
1994).  Since then, multiple epidemiological surveys, cohort studies, and case-control 
studies have failed to replicate this finding (Jacobson et al., 1992; B. Kallen & Tandberg, 
1983; Sipek, 1989; Zalzstein, Koren, Einarson, & Freedom, 1990).  These studies report a 
1.2-7.7 risk ratio for cardiac defects in babies exposed to lithium, a significantly lower risk 
than previously estimated (Cohen, et al., 1994).  It is possible that many physicians still 
quote these older risk figures and may not be aware of current teratology data.  While 
teratology information services in Canada and Italy report that the two drug classes most 
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frequently queried are SSRIs and AEDs (De Santis et al., 2008; Einarson, Park, & Koren, 
2004), physicians comprise less than 10% of phone calls (De Santis, et al., 2008).  A study 
by the Canadian Motherisk Program found that physicians most commonly obtain teratology 
information from 1) the Physicians Desk Reference (PDR), 2) textbooks, 3) peer-reviewed 
journals, and 4) colleagues; sources that may not contain the most up-to-date information 
(Einarson, et al., 2004). 
 
FDA drug classes 
 In addition to outdated risk figures, physicians may also find themselves confused by 
the current United States Food and Drug Administration (FDA) pregnancy risk categories.  
The current FDA drug classification system was created in 1979 with the goal of helping 
physicians make informed decisions about prescribing, continuing, or discontinuing 
medications during pregnancy based on published teratology and reproductive risk data 
(Doering, Boothby, & Cheok, 2002).  Drugs are classified into one of five categories (A, B, 
C, D, and X) based on their risk to the developing fetus, with somewhat of an increasing risk 
from categories A to D, while drugs in category X are contraindicated in pregnancy 
(Erdeljic, Francetic, Makar-Ausperger, Likic, & Radacic-Aumiler, 2010).  FDA drug 
categories are required information in package inserts on all medications manufactured after 
1979, but are not available on 60% of the drugs in the PDR because the regulations did not 
apply to drugs already on the market (Sannerstedt et al., 1996). 
 The current FDA drug categories have faced intense criticism since their 
implementation (Doering, et al., 2002; Erdeljic, et al., 2010).  In general, physicians feel that 
the information provided is “not sufficient to make informed decisions adequately about 
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drug therapy in pregnant women and women of childbearing potential” (Doering, et al., 
2002).  The two most significant problems with the current labeling system are that 
physicians incorrectly perceive 1) a gradation of risk that increases across the categories 
(from A to X), and 2) that drugs in the same category carry the same level and types of risks 
(Doering, et al., 2002).  Further, the labeling system does not provide information on the 
possible negative effects on the developing fetus of the condition associated with the drug 
(e.g. the risks associated with maternal seizures on an anti-epileptic drug label).   
The biggest limitation of the current FDA categorization system is the overall lack of 
human data regarding the teratogenicity of medications, largely due to the ethical restrictions 
prohibiting case-control studies, and the small nature of available retrospective studies and 
case reports (Doering, et al., 2002).  Erdeljic and colleagues feel that relying solely on the 
FDA drug categories in patient counseling can lead to an inappropriate discontinuation of 
medication, an increase in elective terminations of healthy pregnancies, and an overall 
increase in maternal anxiety (2010).  A recent study of 1076 pregnant Croatian women 
evaluated the concordance between clinical pharmacologists’ assessment of medication 
exposures during pregnancy and the current FDA drug categories.  Risk assessments 
provided by the pharmacologists agreed with the FDA categories in only 28% of cases 
(Erdeljic, et al., 2010).  Further, those risk estimates provided by the expert professionals 
were more accurate than those of the drug classes.   
The FDA recognizes the limitations of its current system, and announced in May 
2008 that they plan to replace the A, B, C, D, X system with an easier to use “narrative” 
guide on pregnancy risks, available studies, and clinical recommendations (Feibus, 2008).  
However, these changes have yet to be implemented. 
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Teratology information resources 
While the FDA drug class are a less than ideal resource for teratogen counseling, 
multiple other text and online sources of teratogen information are currently available to 
physicians.  The Physicians Desk Reference (PDR) is a popular reference book and contains 
information on drug labeling and product safety, and is described as “the most trusted and 
commonly used drug information resource” (PDRNetwork, 2010).  The PDR is essentially 
an anthology of prescription drug package inserts (Doering, et al., 2002)  In an increasingly 
technology-reliant clinical setting, many physicians today utilize electronic information 
resources on personal digital assistants (PDAs) such as Epocrates, a physician-compiled 
information database that contains a drug guide, formulary information, and drug interaction 
tool (Epocrates, 2011).  Peer-reviewed web sites are also convenient physician resources.  
The Organization of Teratology Information Specialists (OTIS) is a non-profit teratology 
information service that offers counseling to both physicians and patients in North America 
regarding exposures during pregnancy via both local and national call centers (OTIS, 2010).  
OTIS also offers free patient-friendly drug fact sheets for many common medications and 
exposures encountered during pregnancy.  Finally, the web site Reprotox offers physicians 
detailed reviews of available literature regarding the teratogencity of numerous medications 
(Reprotox, 2011).   
 
Study objective 
Given that many physicians appear to rely on out of date or unreliable information, 
we hypothesize that obstetricians currently quote inaccurate risk figures to women taking 
psychotrophic medications during pregnancy.  We hypothesize that regardless of their 
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knowledge of these medications, most obstetricians overestimate the teratogenic risk to the 
developing fetus, and this greatly impacts their recommendations during pregnancy. 
Therefore, the aim of this study is to determine the current knowledge base of 
obstetricians regarding the teratogenic effects of mood stabilizer, anti-psychotic, and anti-
depressant use during pregnancy, and whether these perceived risks influence their 
recommendations during pregnancy management.  This study will evaluate whether 
obstetricians are up-to-date on current teratology data related to mood disorder treatment, as 
well as how physicians perceive the risks associated with these medications.   This study 
will also investigate which teratology information resources obstetricians utilize in patient 
counseling, if any.  Finally, this project also hopes to elucidate current obstetrician referral 
and management patterns for women with mood disorders.  The ultimate goal of this study 
is to capture the current standard of practice in managing pregnant women with mood 
disorders, as well as further the ongoing dialogue of the importance of education and 
awareness of psychiatric illness during pregnancy.   
 
MATERIALS AND METHODS 
Survey design 
A 26-item questionnaire was designed to assess obstetricians’ medical background, 
experience, and opinions regarding the pharmacological management of women with mood 
disorders during pregnancy.  The questionnaire was divided into four parts: demographics, 
experience and referral patterns, teratogen knowledge and perceptions, and situational 
vignettes.   
The questionnaire contained fill-in-the-blank, multiple choice, and ranking questions.  
Space was available for additional comments at the end of each of the two situational 
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vignettes.  The survey was written in English and was intended to take the respondent less 
than 15 minutes to complete.  The questionnaire was anonymous, and no personal identifiers 
were requested or recorded.  All responses were kept completely confidential.  The 
questionnaire was approved by the Institutional Review Board at the University of Texas 
Health Science Center at Houston Graduate School of Biomedical Sciences (IRB# HSC-
MS-10-0374).  A copy of the survey may be found in Appendix 1. 
 
Population 
 The study population was comprised of all registered members of the Texas 
Association of Obstetricians and Gynecologists (TAOG) as of May 2010.  Members of 
TAOG are obstetrician/gynecologists or gynecologists only that typically practice in the 
state of Texas.  Those physicians with non-Texas addresses were not excluded from the 
study (n=10).  A database of members containing names and mailing addresses was supplied 
directly by TAOG.  Eleven hundred and four active, retired, and physicians in residency 
comprised the list according to TAOG.  Three of the physician listings did not have 
complete mailing addresses and were excluded from the study.  Therefore, 1101 physicians 
were surveyed in total. 
 
Survey Administration 
 The questionnaire was administered in two separate waves.  The first wave of 
questionnaires was distributed to the entire study population (n=1101) on September 16, 
2010.  A cover letter explaining the purpose of the study, its benefits and limitations, and 
completion instructions was included at the beginning of each survey (see Appendix 1).  
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Each survey was packaged with a self addressed stamped envelope (SASE).  Each SASE 
was numbered on the inside flap from 1 to 1101, and these numbers corresponded to a 
numbered but de-indentified database of physician addresses.  The purpose of this 
numbering system was to allow anonymous tracking of which surveys were returned so that 
original responders could be excluded from a second wave of mailing.   
 A Microsoft Excel database was created to track which numbered SASEs containing 
the completed questionnaires had been returned.  Those anonymous “numbers” that had not 
returned a questionnaire by November 1, 2010 (n= 835) were mailed a second questionnaire 
November, 24, 2010.   
 Questionnaires returned to the principal investigator were coded and entered into a 
Microsoft Excel 2007 database.  Each entry was reviewed twice for accuracy.  Collection of 
both first and second wave questionnaires ended Friday, January 14, 2011.   
 
Statistical Analysis 
 Response data was analyzed using Small Stata Version 11.0 (StataCorp, LP, College 
Station, Texas).  Basic summary statistics were performed on all questions with the 
exception of the fill-in-the-blank sections.  Descriptive charts and graphs were created using 
Microsoft Excel 2007.  The two-sample Wilcoxon rank-sum (Mann-Whitney) test was used 
to analyze responses to most questions by three binary categories: age (<50 or ≥50 years), 
gender, and primary practice (academic or private practice).  A p-value cut-off of 0.05 or 
less was designated for statistical significance.  For analysis of Part II Question 6, a 
probability test was utilized to determine statistical significance because physician responses 
were not mutually exclusive.  For those association graphs comparing obstetrician-quoted 
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risk figures and obstetricians’ perceptions of these figures, Fisher’s Exact test was utilized to 
determine statistical significance. 
 
Reclassifications 
 Responses that were left blank were coded as missing data.  Responses were coded 
as “Don’t know” only if that option was specifically checked by the responder, or hand-
written in on a question where “Don’t know” was not an available answer.  Otherwise, these 
responses were coded as missing data.  Responses that were hand written and could be 
logically placed in an available category were reclassified appropriately.  However, if a 
response was at all ambiguous or not easily reclassified, it was coded as missing data.   
Comments hand-written into the margins of pages not designated for additional comments 
were grouped with those comments written in Part IV.  Only questionnaires that had at least 
one non-demographic full section completed were included in statistical analysis.  However, 
surveys that did not have a completed demographics section were included.  Nine returned 
questionnaires were excluded because the responder reported he or she practiced gynecology 
only.   
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RESULTS 
Survey Response 
 The database provided by TAOG included 1101 physicians with addresses.  Of the 
1101 surveys distributed in the first mailing, 261 (24%) were returned by the post office to 
the University of Texas Health Science Center at Houston.  One hundred and seventy-four 
(66%) of those surveys returned were excluded from statistical analysis due to the following: 
no forwarding address (n=153), respondent not actively practicing obstetrics (n=19), or a 
blank survey (n=2).  Those categorized as no longer practicing included physicians who 
were retired, deceased, or practiced gynecology only.  Of the 261 surveys returned, 87 were 
included for statistical analysis, for a first mailing response rate of 10% (87/1101-261). 
 For the second wave of distribution, 840 previous non-respondents were mailed the 
survey again.  Of these, 102 (14%) were returned.  Seventy-two (70%) of these surveys were 
excluded from statistical analysis due to the following: no forwarding address (n=57), 
respondent not actively practicing obstetrics (n=13), or a blank survey (n=2).  Of the 102 
surveys returned, 30 were included for analysis, for a second mailing response rate of 4% 
(30/840-72).  The total response rate for both distributions was 13.6% (117/1101-174-72).   
 In total, 117 surveys were included for statistical analysis in this study.  Respondents 
were selective in which questions they chose to answer, which resulted in different total 
response numbers for each question.  The three categories by which responses were 
stratified during statistical analysis did not have equal numbers due to selective answering: 
age (n=113), gender (n=113), and primary practice (n=109).  Throughout this section, 
percentages are derived from a total survey number of 117, unless otherwise noted.  The 
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number of missing responses is noted for each question analyzed.  The terms “obstetrician” 
and “physician” are used interchangeably. 
 
Part I: Demographics 
 One hundred and five (90%) respondents were general obstetricians, 8 (7%) were 
maternal fetal medicine specialists (specified under “Subspecialty Ob/gyn”), and 4 (3%) did 
not indicate their area of practice.  One of the general obstetricians was also boarded in 
psychiatry (Figure 1).    
 
 Figure 1:  Survey response by area of specialty. 
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 Twenty-three percent (n=27) of physicians reported practicing obstetrics between 0 
and 10 years.  Fifty-seven percent (n=67) reported practicing between 11 and 30 years.  
Thirteen percent (n=15) reported practicing over three decades.  Eight respondents did not 
indicate how long they had been practicing obstetrics (Figure 2). 
 The mean years practiced was 20.11 years, with a range of 0 to 52 years.  The 
median years practiced was 21 years. 
 
 Figure 2:  Survey response by years in practice. 
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 The majority of respondents, 60% (n=70), were between the ages of 41 and 60.  
Nineteen percent (n=22) were over the age of 60 and 18% (n=21) were at or below the age 
of 40.  Three percent (n=4) did not indicate their age (Figure 3).  
 The mean age of respondents was 51.9 years old, with a range of 25 to 82 years old.  
The correlation coefficient for years practiced and age of respondent was 0.95. 
 
 Figure 3:  Survey response by age. 
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 Fifty-seven percent (n=67) of respondents were male, 39% (n=46) were female, and 
4% (n=4) did not specify their gender (Figure 4). 
 
 Figure 4:  Survey response by gender. 
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 In response to Part I Question 6 (Appendix 1), the majority of obstetricians (64%) 
reported working in a private practice setting.  Twenty-seven percent (n=32) reported 
working in an academic or university medical center setting.  Two percent (n=2) reported 
practicing in a Veterans Affairs or military practice, and two percent (n=2) reported 
practicing in public health.  Three percent (n=4) did not specify their area of practice. 
 Four respondents originally selected “Other” for their primary practice setting, and 
wrote in additional information.  These respondents were reclassified as follows: “hospital 
based clinic” and “multidisciplinary group” were designated as private practice, while 
“underserved clinic” and “community hospital” were designated as public health.  These 
four reclassifications are included in the total category percentages as mentioned above and 
shown below (Figure 5).  Individuals who selected one of the four main practice categories 
but wrote in more detail about their practice (e.g. multidisciplinary clinic) were still 
classified by one of the four categories they had originally selected.   
 
 Figure 5:  Survey response by area of practice. 
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Part II: Experience/Referral Patterns 
 Obstetricians were asked how frequently they see women who disclose having a 
mood disorder (depression or bipolar disorder).  Seventeen percent (n=20) reported they see 
women with mood disorders “very often,” or greater than 10 times per month.  Forty-six 
percent (n=54) see women with mood disorders “often” or about 6-10 times per month, 
while 28% (n=33) see these women “sometimes” (2-5 times per month).  Five percent (n=6) 
reported seeing women with mood disorders “rarely,” while no one reported “never” seeing 
these patients (Figure 6).  Four obstetricians (2%) did not respond to this question. 
 
 Figure 6:  Obstetrician-reported frequency of exposure to women who disclose 
 having a mood disorder (per month). 
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 Obstetricians were asked how frequently they refer women who disclose having a 
mood disorder to psychiatric services.  Twenty-nine percent (n=34) reported they “often” 
refer women, while 43% (n=43) reported they “sometimes” refer.  Twenty-nine percent 
(n=34) reported they “rarely” refer, and one (1%) obstetrician reported “never” referring to 
psychiatric services (Figure 7).  Four obstetricians (2%) did not respond to this question. 
 
 Figure 7:  Obstetrician-reported frequency of referrals made to psychiatric services 
 for women who disclose having a mood disorder. 
 
 
 
 
 
 
 
  
0%
10%
20%
30%
40%
50%
60%
Never Rarely Sometimes Often No Response
P
e
rc
e
n
ta
g
e
 o
f 
P
h
y
si
ci
a
n
s
Frequency of Referrals Made to Psychiatric Services 
Frequency of Referrals Made by Obstetricans 
for Women with Mood Disorders
33 
 
 The frequency of referrals made to psychiatric services by obstetricians was 
significantly different by gender (p=0.039), (Figure 8).  Overall, women reported referring 
these patients on a more frequent basis.  Thirty-nine percent (18/46) of responding women 
reported they “often” refer compared to 24% (16/67) of responding men.  In contrast, 30% 
(20/67) of responding men reported “rarely” referring these patients, compared to only 17% 
(8/46) of responding women.   
 There was no significant difference in frequency of referrals made when stratified by 
age (p=0.779) or practice (p=0.070).  There was no significant relationship between the 
frequency of physician exposure to women disclosing mood disorders and the frequency of 
referrals made (p=0.74). 
 
 Figure 8:  Obstetrician-reported frequency of referrals made to psychiatric services 
 for women who disclose having a mood disorder stratified by gender (n=113). 
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 Obstetricians were asked to indicate their level of agreement with the following 
statement: “The obstetrician/gynecologist has a role in referring women for psychiatric 
services.”  Forty-nine percent (n=57) and 37% (n=44) of respondents “strongly agree” and 
“agree,” respectively, that obstetricians have a role in the referral process.  Two percent 
(n=2) neither agreed nor disagreed with the statement.  Ten percent (n=10) of obstetricians 
“strongly disagreed” with the statement (Figure 9).  Two obstetricians (2%) did not respond 
to this question.   
 
 Figure 9:  Obstetrician attitudes towards the following statement: “The 
 obstetrician/gynecologist has a role in referring women for psychiatric services.”   
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 Attitudes towards referring women for psychiatric services were significantly 
different between those obstetricians in private practice and those in an academic or 
university setting (p=0.002).  Those in private practice were more likely to strongly disagree 
or be indifferent towards the statement (Figure 10).  Fourteen percent (11/76) of respondents 
in private practice selected “strongly disagree,” compared to only 3% (1/33) of those in 
academia.  By contrast, 70% (23/33) of respondents in the academic setting “strongly 
agreed, while only 39% (30/76) in private practice chose that response.  
 There was no significant difference in attitudes when stratified by age (p=0.623) or 
gender (p=0.749).   
 
 
 Figure 10: Obstetrician attitudes towards referring women for psychiatric services 
 stratified by obstetrician area of practice. 
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 Obstetricians were asked how often they see women who disclose taking a 
psychotrophic medication (e.g. SSRIs, anti-convulsants, anti-psychotics).  More than half of 
the respondents reported seeing women who disclose this information “very often” (n=18, 
15%) or “often” (n=56, 48%).  Nearly a third (n=36, 31%) reported being exposed to women 
who disclose taking psychotrophics “sometimes,” while 5% (n=4) reported this “rarely” 
happens to them.  Two obstetricians (2%) did not respond to this question (Figure 11).   
 There was no significant difference in the frequency of exposure when stratified by 
age (p=0.918), gender (p=0.406), or practice (p=0.980). 
 
 Figure 11:  Obstetrician-reported frequency of exposure to women who disclose 
 taking a psychotrophic medication. 
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 Obstetricians were then asked how often they discuss psychotrophic medications 
with their patients after patients disclose taking them.  About half (51%, n=60) of 
obstetricians reported discussing these medications “very often.”  Thirty-five percent (n=41) 
reported doing this “often.”  Nine percent (n=10) and 3% (n=4) reported discussing these 
drugs “sometimes” and “rarely,” respectively.  Two physicians (2%) did not respond to this 
question (Figure 12).  There was no significant difference in the frequency of discussions 
when stratified by age (p=0.411), gender (p=0.129), or practice (p=0.112). 
 Of those respondents who reported they “often” and “very often” (n=74) see women 
with who disclose taking medications, 41% (n=31) discuss these medications with their 
patients “often” and 53% (n=39) discuss them “very often.”  Only 1% (n=1) reported 
“rarely” discussing the drugs.  Among those who see these women “sometimes” (n=36), 
72% (n=26) reported talking about these medications either “often” or “very often.”  
Further, among those who “rarely” see these patients (n=5), 100% (n=5) also reported 
discussing psychotropics either “often” or “very often.”  
 
 Figure 12: Obstetrician-reported frequency of discussions with patients regarding 
 psychotrophic drug use during pregnancy. 
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 In Part II Question 6, obstetricians were presented with a list of six commonly used 
teratogen information resources including the following: “Teratogen information services 
(e.g. OTIS),” “Peer-reviewed internet source (e.g. ACOG website, Reprotox),” “Google 
and/or Wikipedia,” “Physician’s Desk Reference,” “Colleague,” and “PDA software (e.g. 
Epocrates).”  Respondents also had the option of selecting “Other” and specifying any 
additional resources that were not listed.  Respondents were instructed to check as many 
sources that applied to them. 
 Based on the high frequency with which they appeared in the “Other” category, two 
new physician resources were added: “Drugs in Pregnancy and Lactation” and “Peer-
Reviewed Literature.”  The first of the two new categories included any variation on the 
name of the Drugs in Pregnancy and Lactation textbook by Briggs and colleagues (e.g. 
“Briggs,” “Drugs in Pregnancy Book,” etc.).  The second new category included the 
responses marked as “Other” that specified peer-reviewed literature sources such as journal 
articles or other textbooks, and these responses were reclassified into “Peer-Reviewed 
Literature.”  Respondents who marked “Other” and wrote that they referenced a colleague 
such as a MFM, genetic counselor, or perinatologist were reclassified as “Colleague” 
regardless of whether they selected that category or not.   Along that same logic, those 
respondents who marked “Other” and wrote in an obvious member of the original eight 
categories without selecting that original category were reclassified into that category.  For 
example, if a respondent selected “Other: UPTODATE website,” this was reclassified as 
“Peer-Reviewed Internet.” 
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 Figure 13 shows the frequency each resource was used by obstetricians to discuss 
medication use during pregnancy.  “Peer-reviewed internet sources” (n=81) and 
“Physician’s Desk Reference” (n=56) were the most commonly chosen resources.  “Personal 
Digital Assistant software” and “Colleague” were selected 43 and 46 times, respectively.  
The less commonly chosen sources were “Teratogen information services” (n=26) and 
“Google and/or Wikipedia” (n=22).  The two new categories, “Drugs in Pregnancy and 
Lactation” and “Peer-Reviewed Literature” were cited 13 and 12 times, respectively (Figure 
13).  Twenty percent (n=23) of respondents only selected one resource.  Fifty-six percent 
selected either two (n=32), or three (n=34) resources.  Twelve percent (n=14) selected four, 
while less than 10% selected 5 or more resources. 
 
 Figure 13:  Resources commonly used by obstetricians to provide drug counseling. 
 
0
10
20
30
40
50
60
70
80
90
N
u
m
b
e
r 
o
f 
P
h
y
si
ci
a
n
s
Resources
Commonly Used Resources for Drug Counseling
40 
 
 There were notable trends in the types of resources used by obstetricians depending 
on their age (Figure 14).  “Google and/or Wikipedia” was selected twice as often by 
obstetricians under the age of 50 (n=14), as those above the age of 50 (n=7), (p=0.07).  In 
contrast, “Drugs in Pregnancy and Lactation” was selected three times as often by 
obstetricians over the age of 50 (n=10), compared to those below the age of 50 (n=3), 
(p=0.08). 
 There was no significant difference in the use of the other resources when stratified 
by age: “teratogen service” (p=0.63), “peer-reviewed internet” (p=0.15), “Physician’s Desk 
Reference” (p=0.15), “colleague” (p=0.59), “personal digital assistant” (p=0.25), and “peer-
reviewed literature” (p=0.71). 
 
 Figure 14:  Obstetrician utilization of common drug counseling resources stratified 
 by age.  †Denotes those resources with notable, although not statistically significant, 
 differences between age groups. 
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 In Part II Question 7, obstetricians were asked to rank four different factors, from 
most contributory (1) to least (5), regarding how they influenced their recommendations for 
pharmacological management during pregnancy.  These factors were “teratogenic risk to the 
fetus,” “risk of relapse in mother if discontinued,” “severity of maternal illness,” and 
“medical liability.”  The “Other” option was available as a write-in option for respondents to 
list any additional factors that may influence their recommendations. 
 Many obstetricians did not rank in a mutually exclusive and non-overlapping 
sequential “1, 2, 3…” order.  For example, some respondents gave all four factors equal 
ranks of “1.”  Individuals who gave equal ranks to more than one category were coded as 
such.  For example, if a respondent ranked the first two factors both “1,” they were coded as 
“1” and “1” each.  However, the next lowest category they ranked was coded as “3” and not 
“2.”  For example, consider the following response: “Teratogenic risk to fetus”(1), “Risk of 
relapse in mother if discontinued” (2), “Severity of maternal illness” (1), “Medical liability” 
(3), “Other” (4).  This would be coded as “1, 3, 1, 4, 5,” respectively.  Many respondents left 
different factors blank after ranking only a few, and these were coded as missing data.   
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 Fifty-one percent (n=64) of respondents who ranked “Teratogenic risk to fetus” 
chose it as the most contributory factor (Rank 1) influencing their decision-making.  The 
most common factor to be given Rank 2 was “Severity of Maternal Illness” (n=49; 45% of 
respondents for that category).  “Risk of relapse in mother if discontinued” was most 
commonly given Rank 3 (n=48; 43% of respondents for that category).  The least 
contributory factor (Rank 4) most commonly selected was “Medical liability” (n=82; 80% of 
respondents for that category).  Eleven obstetricians ranked “Other” factors that influenced 
their decisions, either at Rank 4 or 5 (Figure 15).  Examples of “Other” factors include the 
following: “cost,” “side effects,”  “lack of available counseling,” and “intellectual capability 
of the mother.”  A full list of “Other” factors respondents listed is located in Appendix 2.  
 
 
 Figure 15:  Obstetrician rankings of those factors that influence their 
 recommendations regarding pharmacological management during pregnancy.  Rank 
 1 is most contributory while rank 4 or 5 is least contributory. 
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Part III: Teratogen Knowledge/Perceptions 
  
 In Part III, a series of five paired questions was utilized to assess obstetricians’ 
knowledge of accurate teratogenic risk figures associated with common psychotropic 
medications (e.g. SSRIs, anti-psychotics), as well as obstetricians’ perceptions of these risks.  
In this section a few respondents did not select an available answer but wrote in their own 
answer next to the question.  This typically occurred with those questions requesting a 
specific risk figure.  If the hand-written response could be logically placed in an available 
category, the answer was reclassified.  For example, if a responder wrote the incidence of 
structural birth defects was “7%” for exposure to SSRIs in utero, this could easily be placed 
in the “5-10%” answer category.  However, if the response was at all ambiguous or not 
easily reclassified, it was coded as missing data.  Those individuals who wrote in “I don’t 
know” or similar statements were reclassified as “Don’t know” if the question had that 
category available.  Otherwise, these responses were coded as missing data. 
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 Obstetricians were asked how comfortable they are discussing the teratogencitiy of 
medications used to manage mood disorders with their patients.  Sixty-four percent (n=76) 
reported feeling “comfortable” and 12% (n=15) reported feeling “very comfortable,” while 
14% (n=17) were “uncertain.”  Five (n=6) and 2% (n=3) reported feeling “uncomfortable” 
or “very uncomfortable,” respectively, when having these discussions (Figure 16).  There 
was no significant difference in comfort level when stratified by age (p=0.607), gender 
(p=0.523), or practice (p=0.421). 
 
 
 Figure 16:  Obstetrician-reported level of comfort when discussing the 
 teratogenicity of psychotrophics with their patients. 
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 Obstetricians were asked what incidence of structural birth defects they quote to 
patients taking selective serotonin reuptake inhibitors (SSRIs) during pregnancy.  Of those 
who responded (n=110), the majority (n=41; 37%) selected “Don’t Know.”  Twenty-four 
percent (n=26) selected the correct value of 2/1000.  Eighteen percent (n=20) 
underestimated the risk at 2/10,000, while 20% (n=22) and 1% (n=1) overestimated the risk 
at 2/100 and 2/10, respectively (Figure 17). 
 There was no statistically significant difference in quoted risk when stratified by age 
(p=0.356), gender (p=0.927), or practice (p=0.293).  Twenty-four percent (8/33) of 
obstetricians from academia and 24% (18/76) of obstetricians from private practice selected 
the correct answer.  Nineteen percent (10/53) of obstetricians at or below the age of 50 
selected the correct answer, compared to 18% (11/60) above the age of 50.  
 
 
 Figure 17:  Obstetrician-quoted incidence of structural birth defects due to in utero 
 SSRI exposure.  *Denotes the correct answer. 
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 Obstetricians were next asked how they perceive the risks associated with taking 
SSRIs during pregnancy.  Of those who responded (n=116), the majority (n=92; 79%) felt 
the risk was “low.”  Nineteen percent (n=22) felt the risk was “moderate,” while only 1 
responder (less than 1%) thought the risk was “high.”  No obstetricians felt the risk for 
structural birth defects was “very high” (Figure 18).  There was no significant difference in 
SSRI risk perception when stratified by age (p=0.836), gender (p=0.071), or practice 
(p=0.887). 
 
 
 Figure 18:  Obstetrician perceptions of the risk for structural birth defects  associated 
 with SSRI exposure. 
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  There was no significant association between quoted risk figures for SSRI exposure, 
and obstetricians’ perceptions of these risks (p=0.455).  Regardless of the exact risk number 
quoted, the majority of respondents felt the risk was low.  Figure 19 shows th
quoted risk figures plotted against obstetrician perceptions of these risks.  
 
 Figure 19:  Obstetrician
 obstetrician perception of risk regarding SSRI use during pregnancy.
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 Obstetricians were also asked what incidence of neural tube defects they quote to 
patients taking valproic acid (Depakote®) during pregnancy.  Of those who responded 
(n=114), the majority (n=49; 43%) selected the correct incidence of 1-2%.  Thirty-two 
percent (n=37) of respondents overestimated the incidence at 5-10%.  Four respondents 
(4%) overestimated the incidence at 20% or higher.  Only 3% (n=3) of obstetricians 
underestimated the risk, while 18% (n=21) of obstetricians selected “Don’t Know” (Figure 
20).   
 There was no statistically significant difference in quoted risk when stratified by age 
(p=0.328), gender (p=0.930), or practice (p=0.557).  Forty-five percent (15/33) of 
obstetricians from academia and 42% (32/76) of obstetricians from private practice selected 
the correct answer.  Forty-five percent (24/53) of obstetricians at or below the age of 50 
selected the correct answer, compared to 40% (24/60) above the age of 50.  
 
 Figure 20:  Obstetrician-quoted incidence of structural birth defects due to in utero 
 valproic acid exposure.  *Denotes the correct answer. 
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 Obstetricians were next asked how they perceive the risk for neural tube defects 
associated with taking valproic acid during pregnancy.  Of those who responded (n=115), 
the majority (n=47; 40%) felt the risk was “moderate.”  Thirty-one percent (n=36) felt the 
risk was “high,” and 15% (n=17) felt the risk was “very high.”  Thirteen percent (n=15) of 
respondents felt the risk was “low” (Figure 21).  There was no significant difference in the 
perceived risk of valproic acid exposure when stratified by age (p=0.255), gender (p=0.257), 
or practice (p=0.340). 
 
 Figure 21:  Obstetrician perceptions of the risk for neural tube defects associated 
 with valproic acid exposure. 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
45
50
Low Moderate High Very High Don't Know No Response
N
u
m
b
e
r 
o
f 
P
h
y
si
ci
a
n
s
Perceived Risk
Perceived Risk of Valproic Acid Exposure, 
N=117
  There was not a significant association between quoted risk figures for valproic acid 
exposure, and obstetricians’ perceptions of these risks (p=0
wide variation in risk perception for the same categories.  For example, 49 respondents 
chose a 1-2% incidence of neural tube defects.  Twenty percent (n=10) felt the risk was 
“low,” 43% (n=21) felt the risk was “moderate,” 2
10% (n=5) felt the risk was “very high.”  Similar differences in risk perception for the same 
risk figure can be seen in other incidence categories (e.g. 5
respondents who selected an inc
“moderate” or “high” risk, compared to those who selected the lower incidence of 1
general, as the risk quantification increases, those obstetricians perceiving the risk as “low” 
decreases (Figure 22).   
 Figure 22: Obstetrician
 obstetrician perception of risk regarding valproic acid use during pregnancy.
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 Obstetricians were asked what incidence of birth defects they quote to patients taking 
lamotrigine (Lamictal®) during pregnancy.  Of those who responded (n=96), the majority 
(n=65, 68%) selected the correct answer, “Not increased above the background.”  Twenty-
eight percent (n=27) of obstetricians selected 5-10%, and only one obstetrician chose 15%.  
No one selected a birth defect incidence of 20% or higher.  Twenty-one obstetricians did not 
respond to this question (Figure 23). 
 There was no statistically significant difference in quoted risk when stratified by age 
(p=0.113), gender (p=0.069), or practice (p=0.718).  Sixty-one percent (20/33) of 
obstetricians from academia and 55% (42/76) of obstetricians from private practice selected 
the correct answer.  Fifty-five percent (29/53) of obstetricians at or below the age of 50 
selected the correct answer, compared to 58% (33/60) above the age of 50.  
 
 Figure 23:  Obstetrician-quoted incidence of birth defects due to in utero 
 lamotrigine exposure.  *Denotes the correct answer. 
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 Obstetricians were next asked how they perceive the risk associated with taking 
lamotrigine during pregnancy in comparison with the risk associated with valproic acid.  Of 
those who responded (n=114), 59% (n=67) felt that lamotrigine has “less risk than valproic 
acid.”  Seven percent (n=8) felt that lamotrigine has the same risk as valproic acid, while 4% 
(n=5) felt that lamotrigine has “more risk than valproic acid.”  Thirty percent (n=34) of 
respondents selected “Don’t know” (Figure 24). 
 There was no significant difference in the perceived risk of lamotrigine exposure 
when stratified by age (p=0.108), gender (p=0.766), or practice (p=0.867). 
 
 Figure 24:  Obstetrician perceptions of the risk for birth defects associated with 
 lamotrigine use during pregnancy, in comparison to valproic acid. 
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  There was a significant association between quoted risk figures for lamotrigine 
exposure, and obstetricians’ perceptions of these risks (p<0.001).  Of the 66 respondents 
who chose a risk “not increased above the background,” 77% (n=51) thought this 
qualification was of less risk than valproic acid.  However, 15% (n=10) thought this 
qualification was equal to the risk associated with valproic acid.  Of the 33 respondents who 
selected “Don’t know” for the risk figure associated with lamotrigine, 36% (n=12) fe
risks associated with the two drugs are equal, while 36% (n=12) reported that did not know 
how they felt about the comparison.  Figure 25 shows the obstetrician
plotted against obstetrician perceptions of these risks.  
 Figure 25: Obstetrician
 obstetrician perception of risk regarding lamotrigine use during pregnancy.
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 Obstetricians were asked what incidence of congenital heart defects they quote to 
patients taking lithium during pregnancy (in relation to the background risk of heart defects).  
Of those who responded (n=112), 49% (n=55) selected the correct value of “less than a 10-
fold increase” in the incidence of heart defects.  Thirty-four percent (n=38) selected “Don’t 
know.”  Four percent (n=5) of respondents underestimated the risk associated with lithium 
use (“no increase”), while 13% (n=14) overestimated the incidence of heart defects.  Of 
note, two obstetricians (2%) selected a “greater than 400-fold increase” in the incidence of 
heart defects (Figure 26). 
 There was no statistically significant difference in quoted risk when stratified by age 
(p=0.219), gender (p=0.975), or practice (p=0.112).  Sixty-one percent (20/33) of 
obstetricians from academia and 45% (34/76) of obstetricians from private practice selected 
the correct answer.  Forty-seven percent (25/53) of obstetricians at or below the age of 50 
selected the correct answer, compared to 58% (29/60) above the age of 50. 
 
 Figure 26:  Obstetrician-quoted incidence of congenital heart defects due to in utero 
 lithium exposure.  *Denotes the correct answer. 
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 Obstetricians were next asked how they perceived the risk for heart defects 
associated with taking lithium during pregnancy.  Of those who responded (n=116), 36% 
(n=42) felt the risk was “moderate,” while 25% (n=29) felt the risk was “high.”  Ten percent 
(n=12) of respondents felt the risk was “very high.”  Only 10 obstetricians (8%) responded 
“Don’t Know” (Figure 27). 
 
 Figure 27:  Obstetrician perceptions of the risk for congenital heart defects 
 associated with lithium use during pregnancy. 
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 There was no significant difference in the perceived risk of lithium exposure when 
stratified by age (p=0.424) or gender (p=0.495).  However, there was a significant difference 
in the perceived risk of lithium when stratified by area of practice (p=0.014).  Of those 
obstetricians who selected a risk perception of “high” (n=27), 74% (n=20) were in private 
practice while the remaining 26% (n=7) practiced in an academic setting.  In addition, of 
those who selected a risk perception of “very high” (n=12), 83% (n=10) were in private 
practice while 17% (n=2) were in academia (Figure 28).  
 
 Figure 28:  Obstetrician perceptions of the risk for congenital heart defects 
 associated with lithium use during pregnancy stratified by area of practice. 
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  There was a significant difference between quoted risk figures for lithium exposure, 
and obstetricians’ perceptions of these risks (p=0.002), (Figure 29).  Fifty
chose an incidence of “less than a 10
this incidence differently.  Twenty
44% (n=24) felt the incidence was “moderate.”  Twenty
incidence of heart defects was “high,” and 7% (n=4) felt it was “v
variations in perception were associated with those 38 obstetricians who were not able to 
select an exact incidence (e.g. those who chose “Don’t know”).  However, individuals who 
selected a “less than 10-fold increase” were more likely 
compared to those who selected “Don’t know.”  Individuals who were not able to quantify a 
risk (“Don’t know”) were more likely to perceive the risk as “high” or “very high.” 
  
 Figure 29: Obstetrician
 obstetrician perception of risk regarding lithium use during pregnancy.
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 Obstetricians were asked what incidence of birth defects they quote to patients taking 
second-generation antipsychotics (e.g. aripiprazole, clozapine, resperidone) during 
pregnancy.  Of those who responded (n=98), 65% (n=64) selected the correct incidence of 
“not increased above the background.”  Twenty-eight percent (n=27) overestimated the 
incidence at 5-10%.  One physician each selected an incidence of 15% and greater than 20% 
(1% each), (Figure 30). 
 There was no statistically significant difference in quoted risk when stratified by age 
(p=0.056), gender (p=0.066), or practice (p=0.343).  Fifty-five percent (18/33) of 
obstetricians from academia and 55% (42/76) of obstetricians from private practice selected 
the correct answer.  Forty-nine percent (26/53) of obstetricians at or below the age of 50 
selected the correct answer, compared to 60% (36/60) above the age of 50. 
 
 
 Figure 30:  Obstetrician-quoted incidence of birth defects due to in utero second-
 generation antipsychotic exposure.  *Denotes the correct answer. 
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 Obstetricians were next asked how they perceived the risk for birth defects 
associated with taking second-generation antipsychotics during pregnancy.  Of those who 
responded (n=100), the majority (55%, n=55) thought the risk was “low.”  Twenty-nine 
percent (n=29) of respondents selected “Don’t know.”  Twenty-four percent (n=24) of 
obstetricians felt the risk was “moderate,” while only 2% (n=2) felt the risk was “high” 
(Figure 31).   
 There was no statistically significant difference in perceived risk when stratified by 
age (p=0.684), gender (p=0.170), or practice (p=0.717). 
 
 Figure 31:  Obstetrician perceptions of the risk for birth defects associated with 
 second-generation antipsychotic use during pregnancy. 
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  There was a significant association between quoted risk figures for second
generation antipsychotic exposure, and obstetricians’ perceptions of these risks (p<0.001).  
Sixty-four respondents quantified that the incidence was “not increased above the 
background.”  However, these respondents perceived this incidence differently.  Seventy 
percent (n=45) of these respondents thought that qualification was “low,” 8% (n=5) thought 
it was “moderate,” and 2% (n=1) thought it was “high.”  Twenty
uncertain how to perceive that incidence (e.g. selected “Don’t know).  Figure 32 shows the 
obstetrician-quoted risk figures plotted against obstetrician perceptions of these risks.  
 Figure 32: Obstetrician
 obstetrician perception of risk regarding second
 pregnancy. 
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Part IV: Situational Vignettes 
 
 In Part IV, obstetricians were asked to evaluate two different situational vignettes 
and answer two questions for each- what recommendations they would make to the patient 
and what (if any) referrals they would make to another provider.  Respondents had the 
option of filling in a particular specialist they would refer to if that option was not listed.  
These “Other” specialists are listed in detail in Appendix 3.  At the end of each situational 
vignette, responders also had the option of writing in additional comments.   
 A detailed description of each vignette can be found in Appendix 1. 
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 Figure 33 shows the distribution of obstetricians’ recommendations in response to 
Vignette 1.  Of those who responded (n=108), the majority (n=48; 44%) would recommend 
that the patient “switch to a different SSRI, because paroxetine is associated with an 
increased risk for birth defects.”  Twenty-three percent (n=25) would recommend the patient 
“stop taking paroxetine (gradually, in decreased doses) for the remainder of the pregnancy.”   
Eighteen percent (n=19) would recommend the patient “continue taking paroxetine as (her) 
primary care physician prescribed,” while 15% (n=16) would recommend the patient “speak 
with (her) primary care physician before making changes to (her) pharmacological 
management.”   
 There was no statistically significant difference in recommendations when stratified 
by age (p=0.77), gender (p=0.36), or practice (p=0.897).
 
 Figure 33:  Obstetrician recommendations in response to Vignette 1. 
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 Figure 34 shows the distribution of obstetricians’ choice of referrals in response to 
Vignette 1.  Of those who responded (n=109), the majority of obstetricians (37%; n=40) felt 
comfortable managing the case alone and did not feel a referral was necessary.  Twenty-nine 
percent (n=32) would refer the patient to “a psychiatrist to discuss whether or not to 
continue taking paroxetine.”  Twenty-one percent (n=23) would recommend the patient see 
“another specialist to co-manage the pregnancy.”  Of these “Other” specialists, a maternal 
fetal medicine specialist was the most common response (n=12).  Eleven percent (n=12) of 
obstetricians would refer the patient to her “primary care physician to re-discuss 
paroxetine.” 
 There was no statistically significant difference in referrals made when stratified by 
age (p=0.46), gender (p=0.11), or practice (p=0.33). 
 
 Figure 34:  Obstetrician referrals in response to Vignette 1. 
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 Figure 35 shows the distribution of obstetricians’ recommendations in response to 
Vignette 2.  Of those who responded (n=96), the majority (n=46; 47%) would recommend 
the patient “speak with (her) psychiatrist before making changes to (her) pharmacological 
regimen.”  Thirty-one percent (n=30) would recommend the patient “switch to a different 
mood stabilizer, because valproic acid is associated with an increased risk for birth defects,” 
while 18% (n=17) would recommend the patient “continue taking valproic acid as your 
psychiatrist recommended.”  Only 2% of respondents (n=2) recommended that the patient 
“stop taking valproic acid.”  Twenty-one obstetricians did not respond to this question. 
 There was no significant difference in recommendations when stratified by age 
(p=0.817), gender (p=0.054), or practice (p=0.701).   
 
 Figure 35:  Obstetrician recommendations in response to Vignette 2. 
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 Figure 36 shows the distribution of obstetricians’ choice of referrals in response to 
Vignette 2.  Of those who responded (n=96), the majority of obstetricians (55%; n=53) 
would refer the patient to her “psychiatrist to re-discuss taking valproic acid.”  Forty percent 
(n=38) would refer that patient to “another specialist to co-manage the pregnancy.”  Of these 
“Other” specialists, a maternal fetal medicine specialist was the most common response 
(n=30, 79%).  Only 4% of obstetricians (n=4) felt comfortable managing the case alone.  
Twenty-one obstetricians did not respond to this question. 
 There was no statistically significant difference in referrals made when stratified by 
age (p=0.586), gender (p=0.386), or practice (p=0.317). 
 
 Figure 36:  Obstetrician referrals in response to Vignette 2. 
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DISCUSSION 
 In this study, Texas obstetricians were asked about their experience with women who 
disclose having mood disorders, their referral patterns and counseling methods for these 
women, and their knowledge base and opinions regarding the use of different psychotropic 
medications (e.g. SSRIs, AEDs) during pregnancy.  Due to the increasing prevalence of 
mood disorders in the general population, and the widespread use of psychotropic 
medications to treat them, it was hypothesized that the average obstetrician frequently 
encounters women with depression or bipolar disorder taking psychotropics during 
pregnancy.  Further, due to a lack of explicit management guidelines, and the variable and 
often discordant array of available drug safety information, it was thought that many 
obstetricians incorrectly counsel their patients regarding the teratogenicity of these 
medications.  In turn, it was hypothesized that this practice could lead to adverse pregnancy 
outcomes.  The ultimate purpose of this study was to capture the current knowledge base 
and practice recommendations of obstetricians treating women taking psychotropic 
medications for mood disorders during pregnancy. 
 
Study Population 
 Over half (57%) of respondents were male, most (60%) were between the ages of 41-
60, and most (57%) had practiced between 11-30 years.  The vast majority indicated they 
practiced general obstetrics (90%).  While the overall study population is not a particularly 
heterogeneous group, it likely represents an accurate sample of those individuals who 
currently practice obstetrics in Texas.  In general, most respondents were in their 50s, had 
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been practicing for at least 20 years, typically practiced in a private setting, and were most 
often male. 
 
Exposure and Referral Patterns 
 The majority (46%) of respondents indicated they see women who disclose having a 
mood disorder “often” or “very often” (17%).  Notably, only 5% reported seeing these 
women “rarely,” and no one reported they “never” see these types of patients.  It can be 
concluded from this response that it is most likely common for obstetricians to encounter 
women with mood disorders in their practice.   
 Most (43%) respondents indicated they “sometimes” refer these women to 
psychiatric services.  However, almost one-third reported that they “rarely” refer women 
who disclose mood disorders to mental health providers, suggesting a missed opportunity to 
refer for psychiatric care during pregnancy, especially if the patient does not currently have 
a mental health care provider and the obstetrician is her primary physician.  Female 
respondents were more likely than male respondents to report referring women to 
psychiatric providers (p=0.039).  While it could be suggested that female physicians might 
be more “in tune” to the emotional and physical challenges of pregnancy, the significance of 
this difference is most likely due to the small sample size of the study (n=117). 
 While almost one-third of respondents reported that they “rarely” refer to psychiatric 
services, 86% either “agreed” or “strongly agreed” that the obstetrician “has a role in 
referring women for psychiatric services.”  This suggests discordance between how 
obstetricians feel and how they actually practice.  It is possible barriers to the referral 
process exist, such as availability of psychiatrists in the area, willingness of these 
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psychiatrists to see pregnant women, and lack of insurance coverage for mental health 
services.  Indeed, the majority of comments made at the end of this survey were related to 
obstetricians’ desire to refer their patients for psychiatric evaluations, but their reported 
inability to do so due to various challenges.  One respondent wrote: 
 The issue is not if psychiatric consultation is needed, rather, the availability of timely 
 and adequate consultation.  The vast majority of psychiatrists in private practice 
 refuse to see and/or treat pregnant patients.  Few take Medicaid and getting 
 appointments in county clinics is never timely… I would prefer to have all of these 
 patients seen by a psychiatrist, but that is not possible. 
While no known studies have ever documented that psychiatrists are unwilling or even 
refuse to see pregnant patients, this was a very frequent concern of respondents.  It is 
possible psychiatrists are less familiar with pregnancy, and uncomfortable managing a 
clinical situation that could result in a teratogenic exposure.  One obstetrician wrote: 
 I rarely have my OB patients see psych.  I manage with MFM.  There are several 
 reasons for this: 1) often takes a while to get an appt with psych and time is 
 important, 2) often find psych not comfortable with this discussion, 3) rarely do 
 psych docs follow-up with me, send letters, phone calls, etc.   
An additional barrier to psychiatric care listed was cost and insurance coverage.  Many 
private insurance companies have limited coverage for psychiatric services, and psychiatry 
is not covered by Medicaid.  One obstetrician commented, “Most of my patients do not have 
access to psychiatry either because of insurance or cost reasons; very few in network and 
limited access to Medicaid.”  In addition, many respondents commented that psychiatric 
providers are not even available in their communities.  This is not surprising, considering 
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many of these surveys were distributed to rural cities in East and West Texas, and that 
psychiatry is the leading subspecialty area in America that lacks adequate healthcare service 
coverage (Smalley, et al., 2010). 
 Respondents in private practice were more likely to “strongly disagree” with the 
statement “the obstetrician has a role in referring women for psychiatric services” (p=0.002).  
It is possible that those in private practice feel more “specialized” in their practice and are 
less focused on extraneous, non-obstetrical issues compared to someone in academic 
medicine who typically practices within an easily accessible community of various specialty 
providers.  Again, however, the small sample size of this study, and the low number of 
respondents who selected “strongly disagree” (n=10), should be considered as a possible 
explanation of this finding. 
   Most respondents reported seeing women who disclosed taking a psychotropic 
medication, such as an SSRI, AED, or atypical antipsychotic, “often” or “sometimes.”  
Notably, only 5% reported “rarely” seeing women who disclose taking these medications.  
This suggests that not only is it common for obstetricians to see women who disclose they 
have a mood disorder, but it is also common for these women to be taking medications to 
manage these conditions.  Once women disclose taking these types of medications, a 
majority of respondents either “very often” or “often” discuss these medications with their 
patients.   Most of the respondents (64%) reported feeling “comfortable” discussing the 
teratogenicity of these medications with their patients, while only 7% reported feeling 
“uncomfortable” or “very uncomfortable” with these discussions. 
 Based on the responses of this study population, it can generally be concluded that is 
common for the obstetrician to be exposed to women who disclose both having a mood 
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disorder and taking a psychotropic medication.  In addition, about two-thirds of obstetricians 
reported referring these types of patients for outside psychiatric services.  Finally, most 
obstetricians feel they have a role in this referral process.   
 
Counseling Resources 
 The majority of respondents reported they provide drug counseling or information of 
some type to their patients.  One goal of this study was to determine what types of resources 
obstetricians use to obtain teratogen information for their patients.  “Peer-reviewed internet 
sources,” such as ACOG’s website (n=81), and the text “Physician’s Desk Reference” 
(n=56) were the two most commonly selected resources.  Obstetricians also reported using 
“Personal digital assistant software” and “Colleagues” frequently.   
 While electronic resources such as peer-reviewed websites and PDA software likely 
provide the most up-to-date teratogen information available, textbooks such as the 
Physician’s Desk Reference (PDR) and Drugs in Pregnancy and Lactation, however well-
respected, are limited in their ability to provide the most current drug safety information.  A 
new PDR is typically published yearly, while the most updated edition of Drugs in 
Pregnancy and Lactation is from 2008.  The teratogenicity of numerous psychotropics is 
continuously being researched, and new data emerges daily for many medications as more 
observational studies and case reports are published.  Further, many of these texts reference 
the unclear and often misinterpreted FDA drug classification system, which is itself in the 
process of being redesigned (Feibus, 2008).  Therefore, obstetricians are not using the best 
resources to obtain correct teratogen information. 
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 Notably, very few respondents reported utilizing “teratogen information services” 
(n=26) such as the teratogen hotline OTIS.  Teratogen call centers are perhaps one of the 
most accurate and easily accessible resources available to all physicians, yet they have a 
history of being under-utilized (De Santis, et al., 2008).  One respondent wrote at the end of 
his survey, “I wish there were a resource with updated counseling info.” This suggests that 
perhaps obstetricians are not aware of the variety of teratogen counseling resources available 
to them. 
 
Factors that Influence Recommendations 
 Integral to understanding current practice regarding the management of pregnant 
women taking psychotropic medications is identifying those factors that most influence 
obstetricians in their decision-making process.  When respondents were asked to rank four 
factors, “Teratogenic risk to the fetus” was most frequently given the highest rank, and 
“Severity of maternal illness” was most commonly given Rank 2.  While both the pregnant 
woman and the fetus are under the care of the obstetrician, these responses suggest that the 
health of the fetus and any teratogenic risk a medication might pose to that fetus is the most 
important factor to this population when making management recommendations.  Indeed, 
the “Risk of relapse in mother if discontinued” was typically ranked low (Rank 3 or 4) by 
respondents.  It could be interpreted that the obstetrician ultimately feels the most 
responsibility towards the fetus in this complicated situation.  However, most respondents 
did rank “Severity of maternal illness” as the second most contributory factor in their 
decision-making process.  A possible explanation is that obstetricians highly value the health 
and care of the mother with a mood disorder; however, they underestimate the risks 
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associated with discontinuing psychotropic medications mid-pregnancy, while concurrently 
overestimating the teratogenic risks to the fetus.   
 Almost all respondents ranked “Medical liability” as the least contributory factor to 
their management recommendations, a finding not unexpected given the stigma associated 
with valuing such an issue.  However, it is likely that in our litigation-friendly society, this is 
a serious (albeit unspoken) concern of many obstetricians.  Indeed, advertisements for law 
firms recruiting women who took drugs such as Depakote® and Paxil® during pregnancy 
and had a child with complications or birth defects have been aired on television stations 
nationwide.    
 Eleven respondents listed “Other” factors they consider when managing women 
taking psychotropic medications during pregnancy, and these were always given ranks of 
either 4 or 5.  Two respondents cited the availability of a psychiatrist’s input as being 
important to their management plan.  Others focused their attention on the maternal state, 
with such concerns as “inability to wean off medications,” “side effects,” and “intellectual 
capability of the mother.”  The remaining respondents listed “cost,” “other risks to the 
baby,” and “trimester” as factors that influence their decision making.  These responses 
suggest that maternal, fetal, and environmental factors all contribute to a very complicated 
decision-making process for the obstetrician encountering pregnant women taking 
psychotropics. 
 
 
 
 
73 
 
Teratogen Knowledge and Perceptions 
Selective serotonin reuptake inhibitors (SSRIs)  
 The majority of respondents (37%) selected “Don’t Know” when asked what 
incidence of structural birth defects they quote to women taking SSRIs during pregnancy.  
The highest number of respondents who actually selected a numerical value (n=69) selected 
the “correct” risk of 2/1000 (38%).  One-third of those selecting a value overestimated the 
risks associated with SSRIs, while 29% underestimated the risk.  These results suggest that 
the majority of obstetricians do not know the incidence of structural birth defects associated 
with SSRIs.  Further, almost as many obstetricians who chose an answer overestimated the 
risk (33%) as got it correct (38%).   
 There was no significant difference in quoted risk when responses were stratified by 
age (p=0.356) or area of practice (p=0.293).  An equal number of respondents from private 
practice and an equal number of respondents from academia selected the “correct” answer.   
Almost an equal number of respondents below and above the age of 50 selected the 
“correct” answer.  One might expect physicians over the age of 50 to be less accurate in 
their risk counseling if they typically use less updated sources of information (e.g. 
textbooks).  It is also notable that an equal percentage of providers in private practice (24%) 
selected the correct answer as those in academia (24%).  It was suspected that those in 
academic medicine would be more likely to report the correct risk figure, as they are more 
frequently exposed to continuing education opportunities and the results of ongoing 
research.  These results suggest that an obstetrician’s area of practice does not affect his or 
her awareness of current teratogen information. 
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 Despite the wide variability in the actual risk figures obstetricians reported quoting 
to their patients, almost all respondents felt the risk associated with SSRI use was low (79%) 
or moderate (19%).  Thus, regardless of what figure obstetricians quoted, they still felt the 
overall risk to the fetus due to SSRI exposure was low.  Further, only one obstetrician 
selected “Don’t know” in how they perceived the risk of SSRIs, compared to two-thirds of 
respondents in the first question.  This suggests that even if respondents could not select an 
actual risk figure, they still felt the risk was “low.” 
 
Valproic acid (Depakote®) 
 In contrast to the question regarding SSRI exposure, the majority of respondents 
(43%) did report quoting the “correct” 1-2% incidence of neural tube defects to pregnant 
patients taking valproic acid.  However, one-third of respondents overestimated the risk to 
be 5-10%, and 4 respondents even selected an incidence of greater than 20%.  Only 18% of 
respondents reported not knowing the incidence.  These results suggest that obstetricians are 
more familiar with the risks associated with the use of valproic acid during pregnancy than 
those associated with SSRI use during pregnancy.  This may be related to the length of time 
valproic acid has been on the market (circa 1967), as well as the pervasiveness of numerous 
studies on its safety.  However, 35% overestimated the incidence of neural tube defects, 
suggesting that many obstetricians may be quoting incorrect risk figures to their patients.   
 The majority of respondents (40%) felt the risk for neural tube defects due to 
valproic acid exposure was “moderate,” and 31% felt the risk was “high.”  Fifteen percent 
even felt the risk was “very high.”  This data suggests that, in general, respondents felt 
valproic acid was a “riskier” drug than SSRIs.  There was not a  significant difference 
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(p=0.067) between quoted risk figures for valproic acid exposure and how obstetricians 
perceived those risk figures.  However, in this study many respondents selected the same 
risk figure, but reported feeling very differently about it.  For example, perception of the 1-
2% incidence for neural tube defects encompassed the entire spectrum, from “low” to “very 
high.”  Similar variations in perception were also present in the “5-10%” and “Don’t know” 
risk categories.  Therefore, each individual provider may use the same risk figure to make 
very different treatment recommendations based on their personal perception of the drug’s 
risk.  In addition, as obstetricians’ risk quantifications increased, their perception of risk also 
increased.   
 
Lamotrigine (Lamictal®) 
 Similar to valproic acid, respondents were relatively well-informed about the 
teratogenicity of lamotrigine, another antiepileptic medication.  The majority of respondents 
(68%) selected the “correct” answer- that the incidence of structural birth defects due to 
lamotrigine is “not increased above the background.”  However, almost one-third of 
respondents felt the risk for birth defects was as high as 5-10%.  Again, there was no 
significant difference when the responses were stratified by age (p=0.113) or area of practice 
(p=0.718).  Notably, 18% of the total number of surveys analyzed in this study (21/117) did 
not have a response for this question.  It is possible this lack of response was due to lack of 
familiarity with the drug lamotrigine, a less commonly prescribed antiepileptic drug than 
valproic acid. 
 Obstetricians were asked to compare how they felt about the risks associated with 
lamotrigine in comparison to the risks associated with valproic acid.  Most respondents 
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(59%) felt there was less risk associated with lamotrigine, while only 4% felt there was more 
risk with this drug.  Notably, only 2% of the total population did not respond to this 
question, a drastic increase in response rate compared to the previous question.  One 
possible explanation for this finding is that even if obstetricians were unfamiliar with 
lamotrigine and its associated risks, they still thought or assumed it to have less risk to the 
developing fetus than valproic acid.  
 There was a significant (p<0.001) difference between quoted risk figures for 
lamotrigine exposure, and obstetrician’s perceptions of these risks.  Again, respondents who 
selected the same risk figure (e.g. “Not increased above the background), felt very 
differently about this risk when comparing it to valproic acid.  The entire spectrum, from 
“less risk” to “more risk,” was represented.  This would provide another example of a 
psychotropic that is viewed very differently depending on the personal perceptions of the 
providing obstetrician.    
 
Lithium   
 The incidence for congenital heart defects, particularly Ebstein’s anomaly, due to in 
utero lithium exposure is a commonly overestimated risk (Cohen, et al., 1994).  In this study, 
however, the majority of respondents (49%) reported that they quote patients a “less than 
10-fold increase” in the incidence of heart defects, which is the “correct” response.  Only 
13% overestimated the risk, and only 2 respondents reported they use the original risk figure 
of “greater than a 400-fold increase.”  However, a large proportion of respondents (34%) 
selected “Don’t know,” suggesting that many obstetricians are not aware of the exact risks 
associated with lithium use during pregnancy.   
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 There was a significant difference between quoted risk figures for lithium exposure, 
and obstetricians’ perceptions of these risks (p=0.002).  While the majority of obstetricians 
selected a “less than 10-fold increase,” respondents felt very differently about this risk.  
Thirty-six percent felt the risk was “moderate,” 25% felt the risk was “high,” and 10% felt 
the risk was “very high.”  Again, it is possible this wide variability in perception among 
providers could lead to very different management recommendations for patients.  It is also 
possible that while obstetricians are aware of more accurate lithium risk data, the negative 
stigma surrounding lithium use during pregnancy presented decades ago may have a lasting 
impression on their risk perceptions. 
 Notably, while 34% of respondents reported they did not know the exact numerical 
risk associated with lithium exposure, only 8% did not know how they perceived the risk 
associated with lithium exposure.  This suggests that while respondents may have been 
unable to quantify the risks associated with this lithium, most still possessed a qualifiable 
risk perception of the drug.    
 There was a significant difference in how respondents perceived the risks associated 
with lithium exposure when stratified by area of practice (p=0.014).  Obstetricians in private 
practice were more likely to classify lithium’s risk as “high” (n=20 in private practice versus 
n=7 in academia) or “very high” (n=10 in private practice versus n=2 in academia).  It is 
possible obstetricians in private practice are less exposed to women taking lithium and 
therefore perceive it as more dangerous.  However, it is much more likely this significance is 
an artifact of the small sample size of the study. 
 
 
78 
 
Second-generation antipsychotics 
 Due to their recent emergence on the market, it was hypothesized that obstetricians’ 
knowledge of second-generation antipsychotics would be less than that of the other 
psychotropics discussed.  However, the majority (65%) of respondents selected the “correct” 
answer that this class is thus far not associated with any significantly increased risk for birth 
defects above the background.  Twenty-eight percent of respondents did overestimate the 
incidence at 5-10%.   
 Most respondents (55%) perceived the risks associated with in utero exposure to 
second-generation antipsychotics as “low.”  Notably, almost one-third of respondents (29%) 
selected “Don’t know” regarding how they perceive the risk.  This is an almost three-fold 
increase in the number of respondents who chose “Don’t know” compared to the first 
question, which is unusual.  This is the only question pair in which respondents appear to be 
better able to provide a quantified risk figure for a medication than to provide a qualified 
risk perception.   
 Again, there was a significant difference between quoted risk figures and how 
obstetricians perceived these risks (p<0.001).  While the majority of respondents thought the 
risk associated with second-generation antipsychotic use was “not increased above the 
background,” they had variable perceptions of this risk (from “low” to “very high”).  This 
again highlights how different individuals can look at the same risk figure and interpret it 
very differently.   
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Overall Knowledge and Perceptions 
 In assessing this population’s knowledge base of the teratogenicity of five different 
types of psychotropics, the majority of respondents who actually selected a numerical 
answer did select the “correct” figure.  However, in all five sets anywhere from 5 to 37% of 
respondents selected “Don’t know” when asked for a specific risk figure.  When combined 
with those who selected incorrect answers, the majority of obstetricians did not select the 
correct answer.  This suggests a significant knowledge gap in the field of obstetrics 
regarding the teratogenicity of most medications used to treat mood disorders. 
 If respondents were unable to select an exact numerical risk figure for a medication, 
they were typically still able to qualify that risk in terms of “high” versus “low.”  However, 
there were widely discrepant perceptions of the same numerical risk figures among 
responders for all but one set of questions.  This finding suggests that personal perception 
and interpretation of teratogenic risks may play an important role in how obstetricians make 
management recommendations for this patient population.  If so, explicit practice guidelines 
for managing women taking psychotropic medications during pregnancy may be critical for 
uniform risk assessment and equal treatment of individuals in this population. 
  
Situational Vignettes 
 In the last part of the survey, respondents were given two different situational 
vignettes and asked to indicate what, if any, recommendations they would make for the 
patient in the scenario, and who, if anyone, they would refer the patient to for further care.  
Respondents had the opportunity to write-in a provider they would refer to if it was not 
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already listed.  The purpose of these vignettes was to attempt to capture obstetricians’ 
current practice and referral patterns in two very different clinical situations. 
 
Vignette One 
 In the first clinical scenario, the majority of respondents (44%) would recommend 
the patient “switch to a different SSRI” because of the increased risk for birth defects 
associated with paroxetine.  Notably, 23% of respondents would recommend the patient 
“stop taking paroxetine” for the remainder of the pregnancy.  Only 15% recommended the 
patient “speak with (her) primary care physician” before changing her drug regimen.  This 
suggests that obstetricians feel it is within their scope of practice to make pharmacological 
regimen changes for pregnant patients with moderate depression, even changes as drastic as 
complete cessation of SSRI use for the remainder of the pregnancy.  In fact, one respondent 
wrote they feel comfortable with recommending cessation because “I find pregnant women 
are motivated to do well off medication.”      
 In addition to feeling it is within their practice to make pharmacological regimen 
changes for this patient, 37% of respondents indicated they would manage the case alone 
and did not feel a referral to another provider was necessary.  About one-third of 
respondents thought the patient should see a psychiatrist to see if taking paroxetine was 
necessary, while 20% felt a specialty consultation, typically with a maternal fetal medicine 
specialist, was warranted.  Therefore, over one-half of respondents did not feel comfortable 
managing this case alone.  This is striking considering the majority of respondents (79%) 
reported earlier that they felt the risk for structural birth defects associated with SSRI 
exposure was “low.” However, only 24% of respondents reported the correct incidence of 
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structural birth defects associated with SSRI use.  This suggests discordance between how 
obstetricians think and feel about a medication’s teratogenicitiy, and how they actually 
practice.  
 It is possible the slightly elevated risk for congenital heart defects and the recent 
negative publicity surround paroxetine could contribute to those obstetricians who feel more 
comfortable consulting a specialty provider.  Overall, the responses to this vignette 
demonstrate a wide variety of practice and management recommendations among 
obstetricians. 
 
Vignette Two 
   In contrast to the responses to the first vignette, 47% of obstetricians would 
recommend the patient in the second clinical situation speak with her psychiatrist first before 
changing her pharmacological regimen.  One third of respondents would recommend the 
patient switch to a different mood stabilizer because of the risks associated with valproic 
acid.  Notably, only 2% of respondents would recommend the patient stop taking valproic 
acid completely.  This response is in stark contrast to the first vignette, in which 23% of 
obstetricians recommended drug cessation.  These results suggest obstetricians are far less 
comfortable making recommendations for patients with bipolar disorder or for patients 
taking high doses of valproic acid, or both. 
  Indeed, most respondents were uncomfortable with managing this case alone.  The 
majority selected that they would either refer the patient to a psychiatrist to discuss taking 
valproic acid (46%), or to another specialist to co-manage the pregnancy (33%).  This 
suggests that while obstetricians reported they were comfortable providing drug counseling 
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to their pregnant patients, some indications or medications may reside outside their “comfort 
zone.”  Many respondents wrote in their reasoning for referring the patient to an outside 
provider.  The most common concern was for structural birth defects due to valproic acid 
exposure during the period of organogenesis, so many respondents recommend maternal 
fetal medicine consults and increased ultrasound surveillance.  Notably, only one respondent 
recommended the patient also see a genetic counselor to better understand the teratogenic 
exposure and pregnancy options. 
  In general, obstetricians were far less comfortable with the second situational 
vignette.  This is apparent when one considers that 40 out of 113 (35%) respondents felt 
comfortable managing the first situational vignette alone, compared to only 4 of 90 (4%) 
respondents for the second clinical scenario.  There are multiple components of the second 
vignette that could have contributed to respondents’ discomfort.  First, antiepileptic 
medications like valproic acid were typically perceived as “riskier” than SSRIs by 
respondents.  In addition, the patient in the second vignette was taking a dosage of valproic 
acid that is sufficiently high enough, based on established research, to possibly cause birth 
defects.  Differences in the social aspects of the two vignettes may have also affected 
responses.  The first patient was an older, college-educated multiparous woman who only 
reported minor symptoms of depression.  In contrast, the second patient was a young woman 
with an unplanned pregnancy who did not fill out her intake forms and reported manic 
episodes.  Finally, the general perception of bipolar disorder being a more severe mood 
disorder than depression also likely played a significant role in obstetricans’ discomfort with 
the second vignette.          
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 Strengths and Limitations 
 This study provided direct insight into the accuracy of the general obstetrician in 
providing psychotropic risk figures to pregnant women with mood disorders.  Equally as 
important, this survey elicited how providers feel about the risks associated with certain 
medications, which undoubtedly factors into their practice recommendations.  In addition, 
the current practice of obstetricians managing this subset of women in the state of Texas was 
captured via responses to the situational vignettes.  This information could help better define 
how obstetricians are actually managing the ever-growing population of pregnant women 
with mood disorders.  Ultimately, this study and others like it could increase awareness of 
the necessity for accurate drug counseling in this patient population, as well as the need for 
official practice guidelines. 
 This study was limited by a small sample size (n=117), and overall low response rate 
(13.6%).  In addition, the study population was mostly comprised of middle-age men in 
private practice.  Further, the results of this study reflect the thoughts and opinions of 
obstetricians in the state of Texas only.  It is possible that cultural, regional, and religious 
viewpoints may have impacted respondents’ answers.  Therefore, the results of this study 
may not be entirely representative of all obstetricians in the United States.  Finally, this 
study was limited by selective answering on the part of the respondent. 
 
Overall Conclusions and Future Directions 
 Four main conclusions can be drawn from the results of this study.  First, it is 
common for the general obstetrician to encounter women who disclose both having a mood 
disorder and taking a psychotropic medication during pregnancy.  Second, many 
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obstetricians are either not aware of or under-utilize up-to-date drug counseling resources, as 
well as the services of educated providers such as genetic counselors and teratogen hotlines.  
Third, many obstetricians are unaware of or over-estimate the teratogenic risks of many 
medications used to treat mood disorders.  And finally, many obstetricians want to refer 
pregnant patients with mood disorders to psychiatrists for co-management, but are 
reportedly restricted in doing so due to accessibility or insurance issues.   
  The main goal of this study was to capture the current practice of obstetrician-
provided drug counseling and management for pregnant women with mood disorders.  It 
appears that many practicing obstetricians have conflicting views on how to manage women 
with mood disorders and are unaware of the teratogenic potential of various medications 
used to treat mood disorders.  Thus, a future direction would be to distribute this survey on a 
larger scale (e.g. American College of Obstetricians and Gynecologists).  This would 
provide a greater quantity and diversity of data to better define current practice throughout 
the country.  General practice guidelines and educational materials could then be developed.  
An ongoing dialogue regarding the best management of pregnant women with mood 
disorders is vital to the goal of ultimately providing the best healthcare possible for both 
mother and baby. 
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APPENDIX TWO 
 
Responses to Survey Part II: Question 7 
 
“Other” factors that influence obstetrician recommendations for pharmacological 
management during pregnancy: 
 
• need for OB psy contact in pregnancy- best Rx 
• nothing really, I just care about medical liability when making these decisions 
• inability to successfully wean off or psychiatrists recommendation  
• accepting conditions during pregnancy   
• cost 
• side effects 
• other risks to the baby 
• lack of available counseling 
• intellectual capability of mother 
• trimester 
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APPENDIX THREE 
 
Responses to Survey Part IV: Questions 1 and 2 
 
“Other” specialists to co-manage the pregnancy: 
 
Vignette 1 
 
• Psychiatrist, MFM 
• Psychiatrist (n=4) 
• MFM (n=13) 
• MFM or Geneticist 
• Perinatology 
• Psychologist (n=3) 
 
Vignette 2 
 
• Psychiatrist (n=3) 
• MFM (n=30) 
• Perinatologist 
• MFM or genetic counseling 
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